Boston Scientific develops, manufactures, and sells medical devices used in minimally invasive procedures, helping physicians diagnose and treat heart, gastrointestinal, urological, neurological, and cancer conditions. The company sells to hospitals, outpatient clinics, and physician practices in 127 countries, primarily through a direct sales force organized around physician specialty. Boston Scientific operates in two segments: Cardiovascular (~60%+ of revenue) and MedSurg (~35-40%). The Cardiovascular segment includes electrophysiology (EP), where the FARAPULSE Pulsed Field Ablation system for atrial fibrillation has been the company's fastest-growing product since its U.S. launch in early 2024; the WATCHMAN left atrial appendage closure device for stroke prevention; interventional cardiology devices including imaging systems, stents, and balloons; cardiac rhythm management devices including pacemakers and defibrillators; and interventional oncology products. MedSurg includes endoscopy, urology, and neuromodulation devices. Boston Scientific's business model combines capital equipment placement — generators and mapping systems placed at hospitals — with recurring sales of single-use disposables consumed in each procedure. Revenue scales directly with procedure volume. The company is pursuing an "ecosystem" approach in atrial fibrillation by bundling FARAPULSE ablation and WATCHMAN closure into a single concomitant procedure. Boston Scientific also grows through clinical trials to expand indications and secure reimbursement, geographic expansion of newer technologies internationally, tuck-in M&A, and expanding procedures into ambulatory surgery centers.